Trexquant Investment LP Has $2.10 Million Stock Holdings in Penumbra, Inc. (NYSE:PEN)

Trexquant Investment LP reduced its stake in shares of Penumbra, Inc. (NYSE:PEN) by 64.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,854 shares of the company’s stock after selling 16,120 shares during the quarter. Trexquant Investment LP’s holdings in Penumbra were worth $2,103,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of PEN. UMB Bank n.a. increased its holdings in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after buying an additional 70 shares during the period. Mather Group LLC. increased its stake in Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after acquiring an additional 208 shares during the last quarter. Jones Financial Companies Lllp raised its position in Penumbra by 25.0% during the fourth quarter. Jones Financial Companies Lllp now owns 375 shares of the company’s stock valued at $89,000 after purchasing an additional 75 shares in the last quarter. GAMMA Investing LLC raised its position in Penumbra by 160.8% during the fourth quarter. GAMMA Investing LLC now owns 446 shares of the company’s stock valued at $106,000 after purchasing an additional 275 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Penumbra by 43.4% in the 4th quarter. Blue Trust Inc. now owns 730 shares of the company’s stock valued at $173,000 after purchasing an additional 221 shares in the last quarter. Institutional investors own 88.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on PEN shares. Oppenheimer initiated coverage on Penumbra in a research report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 price objective for the company. Citigroup raised their price target on shares of Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. UBS Group lifted their price target on shares of Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. StockNews.com downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $294.47.

Penumbra Stock Down 2.7 %

Penumbra stock opened at $256.30 on Wednesday. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average price is $273.74 and its two-hundred day moving average price is $246.90. The firm has a market capitalization of $9.87 billion, a price-to-earnings ratio of 753.81, a price-to-earnings-growth ratio of 2.83 and a beta of 0.56. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. On average, equities research analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Insider Activity at Penumbra

In other Penumbra news, Director Thomas Wilder sold 360 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $264.58, for a total value of $95,248.80. Following the completion of the sale, the director now directly owns 4,533 shares of the company’s stock, valued at approximately $1,199,341.14. This represents a 7.36 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total transaction of $172,458.00. Following the transaction, the executive vice president now directly owns 66,539 shares in the company, valued at approximately $19,125,304.77. This represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 111,236 shares of company stock valued at $31,222,390. 5.00% of the stock is owned by insiders.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.